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Background/aim: Hyperbaric oxygen therapy (HBOT) causes insulin sensitivity, but the reason for this is not known yet. The aim of
the present study was to investigate the effect of HBOT on insulin sensitivity via resistin, plasminogen activator inhibitor-I (PAI-I), and
adiponectin.
Materials and methods: The study was designed using HBOT and control groups, with eight rats in each group. After 20 days of
HBOT under 2.5 atmospheres for 90 min, the fasting insulin (FI), resistin, PAI-I, homeostatic model assessment of insulin resistance
scores (HOMA–IR), quantitative insulin sensitivity check index (QUICKI), fasting plasma glucose (FPG), triglyceride, and high-density
lipoprotein cholesterol (HDL-C) in the plasma were measured. The resistin, PAI-I, and adiponectin mRNA expression levels were also
measured in the adipose tissue.
Results: Compared to the control group, the FI, FPG, and HOMA-IR scores were significantly lower in the HBOT group, whereas the
HDL-C and QUICKI scores were found to be higher. In addition, the resistin, adiponectin, and PAI-I mRNA expression levels were also
higher in the HBOT group.
Conclusion: The present study demonstrated that the HBOT had regulated the FI, FPG, and HDL-C associated with metabolic syndrome
and diabetes mellitus. Moreover, the study showed that HBOT causes insulin sensitivity by raising adiponectin.
Key words: Adiponectin, insulin, insulin sensitivity, resistin, plasminogen activator inhibitor-I

1. Introduction
Hyperbaric oxygen therapy (HBOT) refers to a medical
application where 100% oxygen is administered for a
certain period of time under atmospheric pressure greater
than 1.4 [1]. Under normal conditions, approximately 97%
of the oxygen in the blood is transported to the tissues
in the form of hemoglobin, while 3% is dissolved in the
plasma [2]. Since under normal atmospheric pressure,
the hemoglobin in arterial blood is nearly saturated with
oxygen in healthy individuals, no significant increase
occurs in hemoglobin-based oxygen whether breathing
100% oxygen under normal pressure or under HBOT.
However, a significant rate of increase in the amount of
oxygen dissolved in the plasma (partial oxygen pressure) is
observed under HBOT [3]. The partial oxygen pressure in
the arterial blood is about 100 mmHg at sea level, whereas
it varies according to applied pressure and may increase up
to 2000 mmHg under HBOT applications [4].
The HBOT is used to treat medical conditions such as
soft tissue infections, radiation damage, thermal burns,

sudden hearing loss, and carbon monoxide poisoning [5].
For various reasons, this method of treatment expedites
the transition of oxygen to damaged tissues and stimulates
collagen synthesis, angiogenesis, the immune response,
and stem cell migration. It also accelerates the healing of
damaged tissues [6,7].
Many studies have shown the association of high glucose
levels with endothelial dysfunction, vascular damage, and
endothelium-dependent vasodilation, the association of
triglyceride levels with the risk of coronary heart disease
(in some studies), and the inverse relationship between
high-density lipoprotein cholesterol (HDL-C) levels and
cardiovascular disease [8–11]. As for insulin resistance, it
may cause metabolic syndrome (MetS), diabetes mellitus
(DM), hypertension, and endothelial dysfunction [12].
Adiponectin is abundantly synthesized by adipose
tissue. During the differentiation of preadipocytes into
adipocytes, its mRNA expression is significantly increased.
Low adiponectin levels are associated with insulin
resistance, type 2 diabetes, and MetS [13].
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The plasminogen activator inhibitor-I (PAI-I) is
presented as a circulating peptide of adipose tissue origin
because of its strong correlation with body adipose tissue
and body mass index. It is an inhibitor of the plasminogen
activator, and acts in the development of type 2 diabetes
and insulin resistance [14,15].
Resistin is synthesized by many tissues including
white adipose tissue. Interestingly, the sites (tissues/cells)
of major synthesis in humans and animals are different.
Resistin transfusion disrupts glucose tolerance and glucose
uptake to adipocytes. Thus, resistin plays an important
role in the development of insulin resistance [16].
Wilkinson et al. reported that HBOT caused insulin
sensitivity [17], but the reason for this is not yet known.
In addition, previous studies have demonstrated that
resistin, PAI-I, and adiponectin are associated with insulin
resistance/sensitivity [13–16].
According to these findings, we hypothesized that
HBOT might cause insulin sensitivity by affecting the
expression of resistin, PAI-I, and adiponectin. Therefore,
in the present study, we aimed to investigate the effect
of HBOT on insulin sensitivity via resistin, PAI-I, and
adiponectin. We also aimed to investigate the effects of
HBOT on the plasma levels of HDL-C, fasting insulin
(FI), fasting plasma glucose (FPG), and triglyceride, the
abnormal levels of which are risk factors for MetS and DM.
2. Material and methods
2.1. Animals and treatments
All procedures performed on rats were carried out with
the approval of the Local Ethics Committee of Animal
Experiments (2017/4/3-2018/4/5). The study was carried
out at the Düzce University Experimental Animal
Application and Research Center between 3 July 2018 and
20 March 2019. Animals were treated in accordance with
the Guide for the Care and Use of Laboratory Animals
(8th edition, National Academies Press). The study was
performed using two groups of eight male Sprague–
Dawley rats weighing 100–160 g. The first group was
defined as the control group. The rats in this group were
fed and housed under the same conditions as the HBOT
group except for the application of HBOT throughout the
experiment. The second group was defined as the HBOT
group. Unlike the control group, HBOT was applied to this
group (2.5 atmospheres, 100% oxygen). Rat feed (Optima,
rat 24/27, Turkey) and water were provided ad libitum.
The HBOT cabinet used in this study was specially
designed of 2.5-mm steel, holding approximately 19 L
and resistant to pressure higher than 2.5 atmospheres
(atm). The environment included a pressure-resistant,
transparent, plexiglass monitoring window (for checking
the health status of the animals), a humidification unit
to moisturize the oxygen entering the cabinet, a cabin
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pressure manometer, and an adjustable automatic valve
(for both exhaust and safety).
The HBOT was conducted in the HBOT cabinet at
the Düzce University Experimental Animal Application
and Research Center. After the rats in the experimental
group were placed in the cabinet, initially, the valve of
the high-pressure oxygen tube was turned on. The valve
of the oxygen regulator was then turned on in order to
increase the pressure in the cabinet gradually, so as not
to exceed 0.1 atm/min. When the pressure in the cabinet
had reached 2.5 atm, a 90-min administration/test period
began. For 90 min, 2 L/min of oxygen was passed through
the humidifier water in the regulator and into the cabinet.
In order to prevent the increasing pressure caused by the
oxygen from entering the cabinet, air was discharged
through the automatic valve adjusted to 2.5 atm pressure.
Thus, the pressure in the cabinet remained constant at
2.5 atm and oxygen circulation in the cabin was ensured.
At the end of the 90-min administration/test period, the
cabinet pressure was gradually reduced. The reduction
was carried out at a rate not exceeding 0.1 atm/min. When
the pressure in the cabinet reached normal atmospheric
pressure, the animals were removed from the cabinet and
placed in their normal feeding area. Finally, the oxygen
tube valve was turned off and the process was complete.
The same procedure was performed every day for 20 days.
Following 20 days of HBOT administration, the
animals were sacrificed by decapitation under anesthesia
(Alfamin 90 mg/kg, Alfazin 10 mg/kg) after one night of
fasting. After decapitation, blood samples were collected in
tubes using a funnel. The abdomen was then immediately
opened and retroperitoneal adipose tissue samples were
excised. All adipose tissues and blood plasmas were stored
at –80 °C until relevant measurements were conducted.
The levels of triglyceride, FI, FPG, and HDL-C were
measured in these plasma samples.
2.2. Measurement of parameters and statistical analysis
The measurements of the rat FPG (66300, Beckman
Coulter, USA), HDL-C (ODC0011, Beckman Coulter,
USA), and triglyceride (66300, Beckman Coulter, USA)
were performed using the autoanalyzer (Beckman
Coulter, AU680, USA) at the Düzce University Faculty of
Medicine Biochemistry Laboratory. The FI (E-EL-R2466,
Elabscience, USA), PAI-I (E0636Ra, Bioassay Technology
Laboratory, PRC), and resistin (E-EL-R0614, Elabscience,
USA) measurements, on the other hand, were performed
at the Düzce University Experimental Animal Application
and Research Center using a purchased enzyme-linked
immunosorbent assay (ELISA) kit. This was carried out
on a microplate reader device (BioTek, 800 TS, USA)
according to the kit protocol.
Total RNA was extracted from the retroperitoneal
adipose tissue using NucleoZOL reagent (Macherey-
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Nagel, Germany). The cDNA was then synthesized from
the total RNA using a kit (ProtoScript First Strand cDNA
Synthesis Kit, BioLabs, USA). The resistin, PAI-I, and
adiponectin mRNA expression levels were measured
from the synthesized cDNA with a real-time quantitative
polymerase chain reaction (RT-qPCR) kit (Ampliqon,
Denmark) on a RT-qPCR device (Roche LightCycler
480 II, Switzerland). The reference gene (Glyceraldehyde
3-phosphate dehydrogenase (GAPDH)), resistin, PAI-I,
and adiponectin primer sequences (Oligomer, Turkey)
are described as shown in Table. The expression results
(measured as fold change) were calculated in accordance
with Livak and Schmittgen [18].
The homeostatic model assessment of insulin resistance
(HOMA-IR) and quantitative insulin sensitivity check
index (QUICKI) scores were calculated using the data
obtained from the FPG and FI measurements according to
the following formulae:
HOMA-IR = FI (µU/mL) × FPG (mmol/L)/22.5
QUICKI = 1/[log (FI) +log(FPG)]) [19].
Conversion factors: Blood glucose 1 mmol/L = 18 mg/
dL and insulin 1U = 0.0347 mg.
The difference between the groups was determined
using the nonparametric Mann–Whitney U test. The
results of the parameters were expressed as mean ±
standard error of the mean (SEM). All analyses were
performed at a 95% confidence interval using SPSS 16.0
(SPSS Inc, Chicago, USA), with p ≥ 0.05 accepted as null
and P < 0.05 as statistically significant.

levels, no significant difference was seen between the
control group and the HBOT group (p = 0.141) (Figure 1).
The HDL-C level of the HBOT group was significantly
higher than that of the control group (p = 0.012) (Figure
1). The FI levels, on the other hand, were significantly
lower in the HBOT group than in the control group (p =
0.013) (Figure 2).

Figure 1. Glucose, triglyceride, and HDL-C levels.
*Compared with the control group (p = 0.016, p = 0.141, p =
0.012, respectively). Values are mean ± SEM. (HDL-C: highdensity lipoprotein cholesterol; HBOT: hyperbaric oxygen
therapy).

3. Results
After 20 days of HBOT administration, FPG, triglyceride,
HDL-C, and FI measurements were performed on the
rat blood plasma. The FPG level of the HBOT group was
significantly lower than that of the control group (p =
0.016) (Figure 1). When compared in terms of triglyceride

Table. Gene and primer sequences.
Gene
Adiponectin
Resistin
PAI-I
GAPDH

Primer

Primer sequences

Left primer

5’TGAAGGGATTACTGCAACCGAA3’

Right primer 5’CTCCTGTCATTCCAGCATCTCC3’
Left primer

5’TGTCCTACATTGCTGGTCAGTC3’

Right primer 5’TTCTCAATCAACCGTCCTCAGG3’
Left primer

5’CGAAATGTGGTCTTCTCTCCCT3’

Right primer 5’CGTCCGCAGTACTGATCTCATT3’
Left primer

5’TAGACAAGATGGTGAAGGTCGG3’

Right primer 5’CTTCCCATTCTCAGCCTTGACT3’

PAI-I:
plasminogen
activator
inhibitor-I;
Glyceraldehyde 3-phosphate dehydrogenase.

GAPDH:

Figure 2. Fasting insulin levels and scores for HOMA-IR and
QUICKI.
*Compared with the control group (p = 0.013, p = 0.012, p =
0.012, respectively). Values are mean ± SEM. (HBOT: hyperbaric
oxygen therapy; HOMA-IR: homeostatic model assessment of
insulin resistance; QUICKI: quantitative insulin sensitivity check
index).
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When HOMA-IR was calculated using the FPG and
FI level values and compared in the control and HBOT
groups, it was discovered to be significantly lower in the
HBOT group (p = 0.012). However, the QUICKI scores of
the HBOT group were significantly higher than those of
the control group (p = 0.012) (Figure 2).
The levels of resistin and PAI-I in the plasma of the
HBOT group were found to be higher than in the control
group (Figure 3). The high level was statistically significant
for PAI-I, but not for resistin (p = 0.027 and p = 0.257,
respectively). The resistin, adiponectin, and PAI-I mRNA
expression levels in the retroperitoneal adipose tissue of the
HBOT group were significantly higher than in the control
group (p = 0.002, p = 0.002, and p = 0.001, respectively)
(Figure 4).

Figure 3. Resistin and PAI-I levels
*Compared with the control group (p = 0.257, p = 0.027,
respectively). Values are mean ± SEM. (HBOT: hyperbaric
oxygen therapy; PAI-I: plasminogen activator inhibitor-I).

Figure 4. Relative mRNA expression levels in adipose tissue
*Compared with the control group (p = 0.002, p = 0.002, p =
0.001, respectively). Values are mean ± SEM. (HBOT: hyperbaric
oxygen therapy; PAI-I: plasminogen activator inhibitor-I).
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4. Discussion
Glucose is the main energy source of tissues. Blood
glucose is obtained via dietary carbohydrates
postprandially, via glycogenolysis in short-term fasting,
and via gluconeogenesis in long-term fasting [20]. High
glucose levels (hyperglycemia) have been associated with
cardiovascular diseases [8]. The present study found that
the FPG level of the control group was significantly higher
than that of the HBOT group (p = 0.016). In previous
studies, it was reported that oxygen application (1.25 atm
pressure, 36% oxygen) significantly decreased FPG levels
in diabetic rats. In a study performed on healthy Wistar
rats, the FPG level of the oxygen treatment group was
significantly lower than in the control group [21]. Cortisol
increases the blood glucose level [22]. Given that HBOT
reduces the level of cortisol [23], it could be stated that
cortisol reduction might have contributed to the reduced
blood glucose levels.
In the present study, the FI level in the HBOT group
was discovered to be lower than in the control group (p
= 0.013), whereas Yasuda, in his study of healthy Wistar
rats, found no significant difference between the HBOT
group and the control group in terms of insulin levels [21].
One reason for the different results encountered between
that study and ours might be that different animal species
were used (Wistar rats vs Sprague–Dawley rats). The
metabolic difference between these two species might have
caused different results. Secondly, the Wistar rat study
was conducted at 1.25 atm pressure and the HBOT was
administered for 6 h. In our study, however, the HBOT
was administered at 2.5 atm pressure for 90 min. There
were also differences in the administration that might have
caused the results to differ.
Insulin resistance is defined as the insufficient effect of
insulin on tissues [24], and is measured using the HOMAIR method [19]. Insulin sensitivity is determined by using
the QUICKI score [19]. Insulin resistance is an important
risk factor in the development of MetS and DM [25]. In
the present study, low HOMA-IR scores and high QUICKI
scores were detected in the HBOT group (p = 0.012 and
p = 0.012, respectively). Because HBOT increases insulin
sensitivity, it may prevent the development of MetS and
DM.
In the present study, it was found that the HDL-C
levels increased significantly in the HBOT group, whereas
no change was observed regarding triglyceride levels (p =
0.012 and p = 0.141, respectively). In a study conducted
on patients with diabetic foot ulcers, the HDL-C level
significantly increased after HBOT administration. On
the other hand, there was no significant change in the
triglyceride levels of the same patients following HBOT
administration [26]. Low HDL-C is frequently seen in
MetS and DM [27]. Considering both animal and clinical
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studies, protective effects against atherosclerosis and
coronary heart diseases have been associated with HDL-C
levels [28,29]. Because HBOT increases the level of
HDL-C, it may reduce the risk of cardiovascular diseases.
In addition, it may positively affect the course of MetS and
DM.
Both clinical and animal studies suggest that HBOT
regulates blood glucose via many signaling pathways or
molecules and leads to insulin sensitivity [30–35]. In the
mouse study of type 1 DM conducted by Limin et al., it was
suggested that with HBOT, more glycogen was stored in
the liver, the ratio of the islet beta-cell area to the total islet
area increased, the plasma total ghrelin level increased, and
the glucose metabolism dysfunction was ameliorated [30].
In an animal study on type 2 DM conducted by Liu et al.,
it was determined that HBOT increased pancreatic beta
cells and both p-Akt and glucose transporter 4 (GLUT-4)
expression in the muscle. The GLUT-4 transports glucose
into the myocyte, where it is then stored as glycogen
and plays an important role in the regulation of glucose
homeostasis. Liu et al. reported that insulin sensitivity
was induced via HBOT by stimulating the Akt signaling
pathway and increasing GLUT-4 expression in the muscle
[31]. In the clinical study conducted by Wilkinson et al.,
HBOT induced acute interleukin-6 (IL-6) increase and
insulin sensitivity in the nondiabetic obese group. Since
IL-6 infusion increases insulin sensitivity, the increase
in IL-6 and insulin sensitivity together was found to be
remarkable [32]. In the clinical study conducted by Xu
et al., it was stated that HBOT reduced plasma glucose,
insulin, and hemoglobin A1c levels and improved
insulin sensitivity in diabetic patients [33]. Vera-Cruz et
al. determined in their study that HBOT contributed to
glucose homeostasis and regulated insulin sensitivity in
patients with type 2 DM. The carotid body functions as a
sensor of glucose and insulin, and surgical removal of its
nerves prevents the development of diet-related metabolic
diseases. Therefore, Vera-Cruz et al. reported that HBOT
might have caused glucose tolerance by blocking carotid
body chemoreceptors [34].
Resistin, PAI-I, and adiponectin are adipokines that
are associated with insulin resistance/insulin sensitivity.
Resistin and PAI-I cause insulin resistance [35,36]. As
for adiponectin, it increases insulin sensitivity [13]. In
our study, both resistin and PAI-I mRNA expressions
were higher in the HBOT group compared to the control

group. Plasma levels of these two parameters versus their
mRNAs were statistically high in PAI-I but not in resistin
(Figure 3). It is stated that protein expression from mRNA
may be repressed in the posttranscriptional process by
microRNAs [37]. Although the resistin mRNA expression
increased significantly in the HBOT group, its plasma
level did not increase significantly. A possible reason for
this may be the repression of protein expression from
the resistin mRNA by microRNAs. All adipokine mRNA
expressions increased in the HBOT group, including the
adiponectin and insulin sensitivity that was observed as a
result. Although the resistin and PAI-I mRNA expressions
were high in the HBOT group, the insulin sensitivity was
raised. A possible reason for this may be that the effect of
adiponectin is more dominant than the effect of resistin
and PAI-I. The increase in adiponectin mRNA was
approximately seven-fold in the HBOT group compared
to the control group, whereas the increases in resistin and
PAI-I mRNA were approximately two-fold (Figure 4). The
high rate of increase in adiponectin mRNA supports this
possible reason. Adiponectin reduces plasma glucose levels
by increasing 5’-adenosine monophosphate-activated
protein kinase, peroxisome proliferator-activated receptor
gamma, and p38 mitogen-activated protein kinase
activities in the liver and muscle. Adiponectin causes
insulin sensitivity through these pathways [13]. Therefore,
insulin sensitivity may have occurred in the HBOT group.
Our study has limitations. The parameter baseline
levels were not measured prior to HBOT. However, the
study groups were randomly selected from animals of the
same age and size.
The data we obtained in this study demonstrated that
HBOT positively affects plasma levels of HDL-C and FPG
(reducing FPG levels, increasing HDL-C). In addition, the
study demonstrated that HBOT causes insulin sensitivity
by increasing adiponectin expression levels and by
reducing insulin levels. Thus, HBOT may be administered
to prevent the occurrence of insulin resistance and
cardiovascular diseases.
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